Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIMNASDAQ:AKANNASDAQ:GNPXNASDAQ:LIPO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$8.85-3.5%$9.11$0.06▼$14.93$6.76M0.98566,370 shs3,647 shsAKANAkanda$1.34+3.2%$1.28$0.93▼$5.08$1.95M1.6197,262 shs23,562 shsGNPXGenprex$0.26-2.6%$0.28$0.20▼$3.97$7.24M-0.54.17 million shs555,814 shsLIPOLipella Pharmaceuticals$0.78-4.9%$2.30$0.62▼$12.00$3.48M-0.08729,737 shs2,156 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%-0.78%-3.17%-3.17%-76.94%AKANAkanda0.00%-7.52%+5.59%+9.92%-69.93%GNPXGenprex0.00%+19.55%-3.59%-21.49%-86.23%LIPOLipella Pharmaceuticals0.00%-13.33%-74.76%-66.60%-77.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.6766 of 5 stars3.50.00.00.03.00.00.0AKANAkanda0.5483 of 5 stars0.03.00.00.00.81.70.6GNPXGenprex1.0396 of 5 stars0.04.00.04.70.00.00.6LIPOLipella Pharmaceuticals1.3245 of 5 stars0.05.00.00.00.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.003,007.34% UpsideAKANAkanda 0.00N/AN/AN/AGNPXGenprex 0.00N/AN/AN/ALIPOLipella Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K46.31N/AN/A$0.20 per share44.25AKANAkanda$840K2.28N/AN/A$3.00 per share0.45GNPXGenprexN/AN/AN/AN/A$0.15 per shareN/ALIPOLipella Pharmaceuticals$536.36K6.50N/AN/A$1.59 per share0.49Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/AAKANAkanda-$4.10MN/A0.00∞N/AN/AN/AN/AN/AGNPXGenprex-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)LIPOLipella Pharmaceuticals-$5.02M-$4.08N/A∞N/A-988.83%-224.08%-172.88%N/ALatest AKAN, AIM, GNPX, and LIPO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025LIPOLipella PharmaceuticalsN/A-$0.64N/A-$0.64N/A$0.13 million5/12/2025Q1 2025GNPXGenprex-$0.82-$0.26+$0.56-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AAKANAkandaN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75AKANAkandaN/A1.391.39GNPXGenprexN/A1.941.94LIPOLipella PharmaceuticalsN/A6.216.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%AKANAkanda1.00%GNPXGenprex14.05%LIPOLipella Pharmaceuticals74.31%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%AKANAkanda20.39%GNPXGenprex8.47%LIPOLipella Pharmaceuticals32.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableAKANAkanda1101.43 million1.14 millionNot OptionableGNPXGenprex2027.82 million25.47 millionNo DataLIPOLipella Pharmaceuticals44.47 million3.03 millionNot OptionableAKAN, AIM, GNPX, and LIPO HeadlinesRecent News About These CompaniesLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - MorningstarJune 27, 2025 | morningstar.comMLipella Pharmaceuticals delisted from Nasdaq, explores relisting options amid ongoing operationsJune 27, 2025 | bizjournals.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq DelistingJune 26, 2025 | finanznachrichten.deLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq DelistingJune 25, 2025 | globenewswire.comNasdaq delists Lipella Pharmaceuticals over rule violationsJune 22, 2025 | investing.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital MarketJune 21, 2025 | finanznachrichten.deLipella stock tumbles after Nasdaq delisting over rule violationsJune 20, 2025 | in.investing.comLipella Pharmaceuticals Announces Delisting from Nasdaq Capital MarketJune 20, 2025 | globenewswire.comLipella Pharmaceuticals Inc. Announces Issuance of U.S. Patent for Advanced Detection Method of Interstitial CystitisJune 17, 2025 | quiverquant.comQLipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic TechnologyJune 17, 2025 | globenewswire.comLipella Pharmaceuticals extends manufacturing pact with Cook MyoSiteJune 5, 2025 | investing.comLipella Re-Signs Manufacturing Collaboration Agreement with Cook MyoSiteJune 4, 2025 | contractpharma.comCLipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical DevelopmentJune 4, 2025 | prismmediawire.comPLipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical DevelopmentJune 4, 2025 | globenewswire.comLipella Pharmaceuticals to appeal Nasdaq noncompliance warningMay 20, 2025 | bizjournals.comLipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International MeetingMay 15, 2025 | prismmediawire.comPLipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International MeetingMay 15, 2025 | globenewswire.comLipella abstract on LP-10 for OLP accepted for presentation at AAOM, EAOMApril 25, 2025 | markets.businessinsider.comLipella Pharmaceuticals Inc.: Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025April 23, 2025 | finanznachrichten.deLipella Reports Additional Positive Data from Phase 2a Trial of LP-310 in Oral Lichen PlanusApril 23, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeAlphabet Enters a Bull Market: Is It Time to Buy?By Ryan Hasson | June 14, 2025View Alphabet Enters a Bull Market: Is It Time to Buy?Will Warner Bros. Discovery’s Split Produce Double the Upside?By Jeffrey Neal Johnson | June 11, 2025View Will Warner Bros. Discovery’s Split Produce Double the Upside?QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's RallyBy Leo Miller | June 27, 2025View QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's RallyAKAN, AIM, GNPX, and LIPO Company DescriptionsAIM ImmunoTech NYSE:AIM$8.85 -0.32 (-3.49%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$8.95 +0.10 (+1.13%) As of 07/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Akanda NASDAQ:AKAN$1.34 +0.04 (+3.15%) As of 07/3/2025 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.Genprex NASDAQ:GNPX$0.26 -0.01 (-2.59%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$0.26 +0.00 (+0.76%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Lipella Pharmaceuticals NASDAQ:LIPO$0.78 -0.04 (-4.85%) As of 07/3/2025 12:40 PM EasternLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
